Bladder Cancer - Molecular Biology
A diverse range of different chromosomal abnormalities have been reported in bladder cancer cells. The most frequently detected genetic abnormality in transitional cell carcinoma (TCC) of bladder is LOH on chromosome 9.
Abnormalities in genes regulating cell cycle control are often seen in advanced bladder cancers, particularly mutations in TP53 and proteins of the G1 checkpoint, especially RB1, CDKN2A (p16) and cyclin D1 (CCND1).
Overexpression of p73 is also common in bladder cancers and some studies have shown that this is associated with disease progression. Differential mucin expression have also been reported in bladder cancers. However, there are conflicting reports about expression specific mucins; MUC1, MUC2 and MUC7.
Uroplakins (membrane proteins) are expressed in both normal and cancerous urothelium and can act as a marker for the detection of metastases and circulating TCC cells.
Gene-Environment Interactions: A number of studies have investigated genes that might modulate the susceptibility to bladder cancer associated with cigarette smoking. These include the NAT1, NAT2, and GSTM1 genes.
See also: Bladder Cancer - clinical resources (22)
Literature Analysis
Mouse over the terms for more detail; many indicate links which you can click for dedicated pages about the topic.
Clicking on the Gene or Topic will take you to a separate more detailed page. Sort this list by clicking on a column heading e.g. 'Gene' or 'Topic'.
Gene | Location | Aliases | Notes | Topic | Papers |
TP53 | 17p13.1 | P53, BCC7, LFS1, TRP53 | -TP53 and Bladder Cancer | 509 | |
FGFR3 | 4p16.3 | ACH, CEK2, JTK4, CD333, HSFGFR3EX | -FGFR3 and Bladder Cancer | 197 | |
CDKN2A | 9p21.3 | ARF, MLM, P14, P16, P19, CMM2, INK4, MTS1, TP16, CDK4I, CDKN2, INK4A, MTS-1, P14ARF, P19ARF, P16INK4, P16INK4A, P16-INK4A | Deletion | -CDKN2A deletion in Bladder Cancer | 159 |
BIRC5 | 17q25.3 | API4, EPR-1 | -BIRC5 and Bladder Cancer | 150 | |
GSTM1 | 1p13.3 | MU, H-B, GST1, GTH4, GTM1, MU-1, GSTM1-1, GSTM1a-1a, GSTM1b-1b | -GSTM1 and Bladder Cancer | 147 | |
NAT2 | 8p22 | AAC2, PNAT, NAT-2 | -NAT2 and Bladder Cancer | 143 | |
TNF | 6p21.33 | DIF, TNFA, TNFSF2, TNLG1F, TNF-alpha | -TNF and Bladder Cancer | 104 | |
RB1 | 13q14.2 | RB, pRb, OSRC, pp110, p105-Rb, PPP1R130 | -RB1 and Bladder Cancer | 71 | |
MTOR | 1p36.22 | SKS, FRAP, FRAP1, FRAP2, RAFT1, RAPT1 | -MTOR and Bladder Cancer | 65 | |
CDKN1A | 6p21.2 | P21, CIP1, SDI1, WAF1, CAP20, CDKN1, MDA-6, p21CIP1 | -CDKN1A Expression in Bladder Cancer | 60 | |
GSTP1 | 11q13.2 | PI, DFN7, GST3, GSTP, FAEES3, HEL-S-22 | -GSTP1 and Bladder Cancer | 58 | |
CASP3 | 4q35.1 | CPP32, SCA-1, CPP32B | -CASP3 and Bladder Cancer | 50 | |
BAX | 19q13.33 | BCL2L4 | -BAX and Bladder Cancer | 49 | |
XRCC1 | 19q13.31 | RCC | -XRCC1 and Bladder Cancer | 45 | |
AR | Xq12 | KD, AIS, AR8, TFM, DHTR, SBMA, HYSP1, NR3C4, SMAX1, HUMARA | -AR and Bladder Cancer | 44 | |
CD44 | 11p13 | IN, LHR, MC56, MDU2, MDU3, MIC4, Pgp1, CDW44, CSPG8, HCELL, HUTCH-I, ECMR-III | -CD44 and Bladder Cancer | 42 | |
PROC | 2q13-q14 | PC, APC, PROC1, THPH3, THPH4 | -PROC and Bladder Cancer | 41 | |
KIT | 4q12 | PBT, SCFR, C-Kit, CD117 | -KIT and Bladder Cancer | 41 | |
ERBB2 | 17q12 | NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19, HER-2/neu | -ERBB2 and Bladder Cancer | 37 | |
PIK3CA | 3q26.32 | MCM, CWS5, MCAP, PI3K, CLOVE, MCMTC, PI3K-alpha, p110-alpha | -PIK3CA and Bladder Cancer | 36 | |
MMP9 | 20q13.12 | GELB, CLG4B, MMP-9, MANDP2 | -MMP9 and Bladder Cancer | 32 | |
AKT1 | 14q32.33 | AKT, PKB, RAC, CWS6, PRKBA, PKB-ALPHA, RAC-ALPHA | -AKT1 and Bladder Cancer | 31 | |
NAT1 | 8p22 | AAC1, MNAT, NATI, NAT-1 | -NAT1 and Bladder Cancer | 30 | |
SRC | 20q11.23 | ASV, SRC1, THC6, c-SRC, p60-Src | -SRC and Bladder Cancer | 29 | |
MUC1 | 1q22 | EMA, MCD, PEM, PUM, KL-6, MAM6, MCKD, PEMT, CD227, H23AG, MCKD1, MUC-1, ADMCKD, ADMCKD1, CA 15-3, MUC-1/X, MUC1/ZD, MUC-1/SEC | Overexpression | -MUC1 and Bladder Cancer | 26 |
VEGFA | 6p21.1 | VPF, VEGF, MVCD1 | -VEGF Expression in Bladder Cancer | 26 | |
CDKN1B | 12p13.1 | KIP1, MEN4, CDKN4, MEN1B, P27KIP1 | -CDKN1B and Bladder Cancer | 26 | |
NRAS | 1p13.2 | NS6, CMNS, NCMS, ALPS4, N-ras, NRAS1 | -NRAS and Bladder Cancer | 23 | |
EZH2 | 7q36.1 | WVS, ENX1, EZH1, KMT6, WVS2, ENX-1, EZH2b, KMT6A | -EZH2 and Bladder Cancer | 23 | |
IL10 | 1q32.1 | CSIF, TGIF, GVHDS, IL-10, IL10A | -Interleukin-10 and Bladder Cancer | 21 | |
CDK4 | 12q14.1 | CMM3, PSK-J3 | -CDK4 and Bladder Cancer | 21 | |
CD82 | 11p11.2 | R2, 4F9, C33, IA4, ST6, GR15, KAI1, SAR2, TSPAN27 | -CD82 and Bladder Cancer | 18 | |
RUNX3 | 1p36.11 | AML2, CBFA3, PEBP2aC | -RUNX3 and Bladder Cancer | 18 | |
CDH1 | 16q22.1 | UVO, CDHE, ECAD, LCAM, Arc-1, CD324 | -CDH1 and Bladder Cancer | 18 | |
H19 | 11p15.5 | ASM, BWS, WT2, ASM1, D11S813E, LINC00008, NCRNA00008 | -H19 and Bladder Cancer | 18 | |
FHIT | 3p14.2 | FRA3B, AP3Aase | -FHIT and Bladder Cancer | 17 | |
STAT3 | 17q21.2 | APRF, HIES, ADMIO, ADMIO1 | -STAT3 and Bladder Cancer | 17 | |
XIAP | Xq25 | API3, ILP1, MIHA, XLP2, BIRC4, IAP-3, hIAP3, hIAP-3 | -XIAP and Bladder Cancer | 16 | |
E2F3 | 6p22.3 | E2F-3 | -E2F3 and Bladder Cancer | 16 | |
FGFR1 | 8p11.23 | CEK, FLG, HH2, OGD, ECCL, FLT2, KAL2, BFGFR, CD331, FGFBR, FLT-2, HBGFR, N-SAM, FGFR-1, HRTFDS, bFGF-R-1 | -FGFR1 and Bladder Cancer | 15 | |
HIF1A | 14q23.2 | HIF1, MOP1, PASD8, HIF-1A, bHLHe78, HIF-1alpha, HIF1-ALPHA, HIF-1-alpha | -HIF1A and Bladder Cancer | 15 | |
CDKN2B | 9p21.3 | P15, MTS2, TP15, CDK4I, INK4B, p15INK4b | -CDKN2B and Bladder Cancer | 14 | |
FGFR2 | 10q26.13 | BEK, JWS, BBDS, CEK3, CFD1, ECT1, KGFR, TK14, TK25, BFR-1, CD332, K-SAM | -FGFR2 and Bladder Cancer | 14 | |
AURKA | 20q13.2 | AIK, ARK1, AURA, BTAK, STK6, STK7, STK15, PPP1R47 | -AURKA and Bladder Cancer | 14 | |
CCNB1 | 5q13.2 | CCNB | -CCNB1 and Bladder Cancer | 14 | |
VEGFC | 4q34.3 | VRP, Flt4-L, LMPH1D | -VEGFC and Bladder Cancer | 13 | |
GPX1 | 3p21.31 | GPXD, GSHPX1 | -GPX1 and Bladder Cancer | 13 | |
ERCC1 | 19q13.32 | UV20, COFS4, RAD10 | -ERCC1 and Bladder Cancer | 13 | |
IGF2 | 11p15.5 | GRDF, IGF-II, PP9974, C11orf43 | -IGF2 and Bladder Cancer | 12 | |
KRT5 | 12q13.13 | K5, CK5, DDD, DDD1, EBS2, KRT5A | -KRT5 and Bladder Cancer | 11 | |
TIMP3 | 22q12.3 | SFD, K222, K222TA2, HSMRK222 | -TIMP3 and Bladder Cancer | 11 | |
PRC1 | 15q26.1 | ASE1 | -PRC1 and Bladder Cancer | 11 | |
KRT20 | 17q21.2 | K20, CD20, CK20, CK-20, KRT21 | -KRT20 and Bladder Cancer | 11 | |
DAPK2 | 15q22.31 | DRP1, DRP-1 | -DAPK2 and Bladder Cancer | 11 | |
STAG2 | Xq25 | SA2, SA-2, SCC3B, NEDXCF, bA517O1.1 | GWS | -STAG2 and Bladder Cancer | 11 |
SNAI1 | 20q13.13 | SNA, SNAH, SNAIL, SLUGH2, SNAIL1, dJ710H13.1 | -SNAI1 and Bladder Cancer | 10 | |
TGFA | 2p13 | TFGA | -TGFA and Bladder Cancer | 10 | |
FAS | 10q23.31 | APT1, CD95, FAS1, APO-1, FASTM, ALPS1A, TNFRSF6 | -FAS and Bladder Cancer | 9 | |
CLMP | 11q24.1 | ACAM, ASAM, CSBM, CSBS | -CLMP and Bladder Cancer | 9 | |
TACC3 | 4p16.3 | ERIC1, ERIC-1 | -TACC3 and Bladder Cancer | 9 | |
ICAM1 | 19p13.2 | BB2, CD54, P3.58 | -ICAM1 and Bladder Cancer | 9 | |
BMI1 | 10p12.2 | PCGF4, RNF51, FLVI2/BMI1, flvi-2/bmi-1 | -BMI1 and Bladder Cancer | 9 | |
JUN | 1p32.1 | AP1, p39, AP-1, cJUN, c-Jun | -c-Jun and Bladder Cancer | 9 | |
FASLG | 1q24.3 | APTL, FASL, CD178, CD95L, ALPS1B, CD95-L, TNFSF6, TNLG1A, APT1LG1 | -FASLG and Bladder Cancer | 9 | |
TGFBR1 | 9q22.33 | AAT5, ALK5, ESS1, LDS1, MSSE, SKR4, ALK-5, LDS1A, LDS2A, TGFR-1, ACVRLK4, tbetaR-I | -TGFBR1 and Bladder Cancer | 9 | |
NME1 | 17q21.33 | NB, AWD, NBS, GAAD, NDKA, NM23, NDPKA, NDPK-A, NM23-H1 | -NME1 and Bladder Cancer | 8 | |
CEACAM5 | 19q13.2 | CEA, CD66e | -CEACAM5 and Bladder Cancer | 8 | |
TERC | 3q26.2 | TR, hTR, TRC3, DKCA1, PFBMFT2, SCARNA19 | -TERC and Bladder Cancer | 8 | |
XRCC6 | 22q13.2 | ML8, KU70, TLAA, CTC75, CTCBF, G22P1 | -XRCC6 and Bladder Cancer | 7 | |
NOS2 | 17q11.2 | NOS, INOS, NOS2A, HEP-NOS | -NOS2 and Bladder Cancer | 7 | |
KLF4 | 9q31.2 | EZF, GKLF | -KLF4 and Bladder Cancer | 7 | |
EPHX1 | 1q42.12 | MEH, EPHX, EPOX, HYL1 | -EPHX1 and Bladder Cancer | 7 | |
AKT2 | 19q13.2 | PKBB, PRKBB, HIHGHH, PKBBETA, RAC-BETA | -AKT2 and Bladder Cancer | 7 | |
HLA-A | 6p22.1 | HLAA | -HLA-A and Bladder Cancer | 7 | |
PPARG | 3p25.2 | GLM1, CIMT1, NR1C3, PPARG1, PPARG2, PPARgamma | -PPARG and Bladder Cancer | 7 | |
GAPDH | 12p13.31 | G3PD, GAPD, HEL-S-162eP | -GAPDH and Bladder Cancer | 7 | |
CDH13 | 16q23.3 | CDHH, P105 | -CDH13 and Bladder Cancer | 7 | |
KRT7 | 12q13.13 | K7, CK7, SCL, K2C7 | -KRT7 and Bladder Cancer | 7 | |
EDNRB | 13q22.3 | ETB, ET-B, ETB1, ETBR, ETRB, HSCR, WS4A, ABCDS, ET-BR, HSCR2 | -EDNRB and Bladder Cancer | 6 | |
GSTO1 | 10q25.1 | P28, SPG-R, GSTO 1-1, GSTTLp28, HEL-S-21 | -GSTO1 and Bladder Cancer | 6 | |
LGALS3 | 14q22.3 | L31, GAL3, MAC2, CBP35, GALBP, GALIG, LGALS2 | -LGALS3 and Bladder Cancer | 6 | |
FSCN1 | 7p22.1 | HSN, SNL, p55, FAN1 | -FSCN1 and Bladder Cancer | 6 | |
HPRT1 | Xq26.2-q26.3 | HPRT, HGPRT | -HPRT1 and Bladder Cancer | 6 | |
BIRC7 | 20q13.33 | KIAP, LIVIN, MLIAP, RNF50, ML-IAP | -BIRC7 and Bladder Cancer | 6 | |
CAMP | 3p21.31 | LL37, CAP18, CRAMP, HSD26, CAP-18, FALL39, FALL-39 | -CAMP and Bladder Cancer | 6 | |
CCND2 | 12p13.32 | MPPH3, KIAK0002 | -CCND2 and Bladder Cancer | 6 | |
LGALS1 | 22q13.1 | GBP, GAL1 | -LGALS1 and Bladder Cancer | 6 | |
DAPK1 | 9q21.33 | DAPK | -DAPK1 and Bladder Cancer | 6 | |
XRCC4 | 5q14.2 | SSMED | -XRCC4 and Bladder Cancer | 6 | |
CCR2 | 3p21.31 | CKR2, CCR-2, CCR2A, CCR2B, CD192, CKR2A, CKR2B, CMKBR2, MCP-1-R, CC-CKR-2 | -CCR2 and Bladder Cancer | 6 | |
ERCC6 | 10q11.23 | CSB, CKN2, COFS, ARMD5, COFS1, POF11, RAD26, UVSS1 | -ERCC6 and Bladder Cancer | 6 | |
COMT | 22q11.21 | HEL-S-98n | -COMT and Bladder Cancer | 6 | |
ARHGDIB | 12p12.3 | D4, GDIA2, GDID4, LYGDI, Ly-GDI, RAP1GN1, RhoGDI2 | -ARHGDIB and Bladder Cancer | 6 | |
PRKDC | 8q11.21 | HYRC, p350, DNAPK, DNPK1, HYRC1, IMD26, XRCC7, DNA-PKcs | -PRKDC and Bladder Cancer | 6 | |
TIMP2 | 17q25.3 | DDC8, CSC-21K | -TIMP2 and Bladder Cancer | 6 | |
MALAT1 | 11q13.1 | HCN, NEAT2, PRO2853, LINC00047, NCRNA00047 | -MALAT1 and Bladder Cancer | 5 | |
HAS3 | 16q22.1 | -HAS3 and Bladder Cancer | 5 | ||
RALA | 7p14.1 | RAL | -RALA and Bladder Cancer | 5 | |
HAS1 | 19q13.41 | HAS | -HAS1 and Bladder Cancer | 5 | |
POLB | 8p11.21 | -POLB and Bladder Cancer | 5 | ||
TEP1 | 14q11.2 | TP1, TLP1, p240, TROVE1, VAULT2 | -TEP1 and Bladder Cancer | 5 | |
MIR10A | 17q21.32 | MIRN10A, mir-10a, miRNA10A, hsa-mir-10a | -miR-10a and Bladder Cancer | 5 | |
LARS | 5q32 | LRS, LEUS, LFIS, ILFS1, LARS1, LEURS, PIG44, RNTLS, HSPC192, hr025Cl | -LARS and Bladder Cancer | 5 | |
DICER1 | 14q32.13 | DCR1, MNG1, Dicer, HERNA, RMSE2, Dicer1e, K12H4.8-LIKE | -DICER1 and Bladder Cancer | 5 | |
STAR | 8p11.23 | STARD1 | -STAR and Bladder Cancer | 5 | |
MMP3 | 11q22.2 | SL-1, STMY, STR1, CHDS6, MMP-3, STMY1 | -MMP3 and Bladder Cancer | 5 | |
NOS3 | 7q36.1 | eNOS, ECNOS | -NOS3 and Bladder Cancer | 5 | |
MAGEA3 | Xq28 | HIP8, HYPD, CT1.3, MAGE3, MAGEA6 | -MAGEA3 and Bladder Cancer | 5 | |
HGF | 7q21.11 | SF, HGFB, HPTA, F-TCF, DFNB39 | -HGF and Bladder Cancer | 5 | |
TSC2 | 16p13.3 | LAM, TSC4, PPP1R160 | -TSC2 and Bladder Cancer | 5 | |
S100A8 | 1q21.3 | P8, MIF, NIF, CAGA, CFAG, CGLA, L1Ag, MRP8, CP-10, MA387, 60B8AG | -S100A8 and Bladder Cancer | 4 | |
LRIG1 | 3p14 | LIG1, LIG-1 | -LRIG1 and Bladder Cancer | 4 | |
GDF15 | 19p13.11 | PDF, MIC1, PLAB, MIC-1, NAG-1, PTGFB, GDF-15 | -GDF15 and Bladder Cancer | 4 | |
CDK1 | 10q21.2 | CDC2, CDC28A, P34CDC2 | -CDK1 and Bladder Cancer | 4 | |
TP73 | 1p36.32 | P73 | -TP73 Overexpression in Bladder Cancer | 4 | |
GSTM3 | 1p13.3 | GST5, GSTB, GTM3, GSTM3-3 | -GSTM3 and Bladder Cancer | 4 | |
GSTO2 | 10q25.1 | GSTO 2-2, bA127L20.1 | -GSTO2 and Bladder Cancer | 4 | |
S100A9 | 1q21.3 | MIF, NIF, P14, CAGB, CFAG, CGLB, L1AG, LIAG, MRP14, 60B8AG, MAC387 | -S100A9 and Bladder Cancer | 4 | |
CCR5 | 3p21.31 | CKR5, CCR-5, CD195, CKR-5, CCCKR5, CMKBR5, IDDM22, CC-CKR-5 | -CCR5 and Bladder Cancer | 4 | |
EREG | 4q13.3 | ER, Ep, EPR | -EREG and Bladder Cancer | 4 | |
FLT1 | 13q12.3 | FLT, FLT-1, VEGFR1, VEGFR-1 | -FLT1 Expression in Bladder Cancer | 4 | |
PIK3R1 | 5q13.1 | p85, AGM7, GRB1, IMD36, p85-ALPHA | -PIK3R1 and Bladder Cancer | 4 | |
CKS2 | 9q22.2 | CKSHS2 | -CKS2 and Bladder Cancer | 4 | |
FGF1 | 5q31.3 | AFGF, ECGF, FGFA, ECGFA, ECGFB, FGF-1, HBGF1, HBGF-1, GLIO703, ECGF-beta, FGF-alpha | -FGF1 and Bladder Cancer | 4 | |
VHL | 3p25.3 | RCA1, VHL1, pVHL, HRCA1 | -VHL and Bladder Cancer | 4 | |
GNAS | 20q13.32 | AHO, GSA, GSP, POH, GPSA, NESP, SCG6, SgVI, GNAS1, PITA3, C20orf45 | -GNAS and Bladder Cancer | 4 | |
LAMC2 | 1q25.3 | B2T, CSF, EBR2, BM600, EBR2A, LAMB2T, LAMNB2 | -LAMC2 and Bladder Cancer | 4 | |
CCNA1 | 13q13.3 | CT146 | -CCNA1 and Bladder Cancer | 4 | |
MGEA5 | 10q24.32 | OGA, MEA5, NCOAT | -MGEA5 and Bladder Cancer | 3 | |
MTRR | 5p15.31 | MSR, cblE | -MTRR and Bladder Cancer | 3 | |
MUC7 | 4q13.3 | MG2 | -MUC7 and Bladder Cancer | 3 | |
HDAC2 | 6q21 | HD2, RPD3, YAF1 | -HDAC2 and Bladder Cancer | 3 | |
XRCC5 | 2q35 | KU80, KUB2, Ku86, NFIV, KARP1, KARP-1 | -XRCC5 and Bladder Cancer | 3 | |
HDAC4 | 2q37.3 | HD4, AHO3, BDMR, HDACA, HA6116, HDAC-4, HDAC-A | -HDAC4 and Bladder Cancer | 3 | |
COL18A1 | 21q22.3 | KS, KNO, KNO1 | -COL18A1 and Bladder Cancer | 3 | |
MMP14 | 14q11.2 | MMP-14, MMP-X1, MT-MMP, MT1MMP, MTMMP1, WNCHRS, MT1-MMP, MT-MMP 1 | -MMP14 and Bladder Cancer | 3 | |
NOX1 | Xq22.1 | MOX1, NOH1, NOH-1, GP91-2 | -NOX1 and Bladder Cancer | 3 | |
RAF1 | 3p25.2 | NS5, CRAF, Raf-1, c-Raf, CMD1NN | -RAF1 and Bladder Cancer | 3 | |
ADGRB1 | 8q24.3 | BAI1, GDAIF | -BAI1 and Bladder Cancer | 3 | |
VIP | 6q25.2 | PHM27 | -VIP and Bladder Cancer | 3 | |
MAP2K6 | 17q24.3 | MEK6, MKK6, MAPKK6, PRKMK6, SAPKK3, SAPKK-3 | -MAP2K6 and Bladder Cancer | 3 | |
UBE2C | 20q13.12 | UBCH10, dJ447F3.2 | -UBE2C and Bladder Cancer | 3 | |
FGF4 | 11q13.3 | HST, KFGF, HST-1, HSTF1, K-FGF, HBGF-4 | -FGF4 and Bladder Cancer | 3 | |
SFRP2 | 4q31.3 | FRP-2, SARP1, SDF-5 | -SFRP2 and Bladder Cancer | 3 | |
ACTB | 7p22.1 | BRWS1, PS1TP5BP1 | -ACTB and Bladder Cancer | 3 | |
PDGFRB | 5q32 | IMF1, KOGS, IBGC4, JTK12, PDGFR, PENTT, CD140B, PDGFR1, PDGFR-1 | -PDGFRB and Bladder Cancer | 3 | |
SMAD2 | 18q21.1 | JV18, MADH2, MADR2, JV18-1, hMAD-2, hSMAD2 | -SMAD2 and Bladder Cancer | 3 | |
IGFBP5 | 2q35 | IBP5 | -IGFBP5 and Bladder Cancer | 3 | |
CALCA | 11p15.2 | CT, KC, PCT, CGRP, CALC1, CGRP1, CGRP-I | -CALCA and Bladder Cancer | 3 | |
XAF1 | 17p13.1 | BIRC4BP, XIAPAF1, HSXIAPAF1 | -XAF1 and Bladder Cancer | 3 | |
RHOA | 3p21.31 | ARHA, ARH12, RHO12, RHOH12 | -RHOA and Bladder Cancer | 3 | |
MAGEA1 | Xq28 | CT1.1, MAGE1 | -MAGEA1 and Bladder Cancer | 3 | |
KRT14 | 17q21.2 | K14, NFJ, CK14, EBS3, EBS4 | -KRT14 and Bladder Cancer | 3 | |
UGT2B7 | 4q13.2 | UGT2B9, UDPGTH2, UDPGT2B7, UDPGTh-2, UDPGT 2B7, UDPGT 2B9 | -UGT2B7 and Bladder Cancer | 3 | |
DEK | 6p22.3 | D6S231E | -DEK and Bladder Cancer | 3 | |
CD47 | 3q13.1-q13.2 | IAP, OA3, MER6 | -CD47 and Bladder Cancer | 3 | |
NCOA1 | 2p23 | SRC1, KAT13A, RIP160, F-SRC-1, bHLHe42, bHLHe74 | -NCOA1 and Bladder Cancer | 2 | |
RREB1 | 6p24.3 | HNT, FINB, LZ321, Zep-1, RREB-1 | -RREB1 and Bladder Cancer | 2 | |
S100P | 4p16.1 | MIG9 | -S100P and Bladder Cancer | 2 | |
HLA-G | 6p22.1 | MHC-G | -HLA-G and Bladder Cancer | 2 | |
MCM5 | 22q12.3 | CDC46, MGORS8, P1-CDC46 | -MCM5 and Bladder Cancer | 2 | |
PTPRF | 1p34.2 | LAR, BNAH2 | -PTPRF and Bladder Cancer | 2 | |
PLAT | 8p11.21 | TPA, T-PA | -PLAT and Bladder Cancer | 2 | |
TNFSF15 | 9q32 | TL1, TL1A, VEGI, TNLG1B, VEGI192A | -TNFSF15 expression in Bladder Cancer | 2 | |
FH | 1q43 | MCL, FMRD, HsFH, LRCC, HLRCC, MCUL1 | -FH and Bladder Cancer | 2 | |
ITGB3 | 17q21.32 | GT, CD61, GP3A, BDPLT2, GPIIIa, BDPLT16 | -ITGB3 and Bladder Cancer | 2 | |
CUL3 | 2q36.2 | CUL-3, PHA2E | -CUL3 and Bladder Cancer | 2 | |
ANXA1 | 9q21.13 | ANX1, LPC1 | -ANXA1 and Bladder Cancer | 2 | |
RXRA | 9q34.2 | NR2B1 | -RXRA and Bladder Cancer | 2 | |
IRF8 | 16q24.1 | ICSBP, IRF-8, ICSBP1, IMD32A, IMD32B, H-ICSBP | -IRF8 and Bladder Cancer | 2 | |
ANXA5 | 4q27 | PP4, ANX5, ENX2, RPRGL3, HEL-S-7 | -ANXA5 and Bladder Cancer | 2 | |
GLI2 | 2q14 | CJS, HPE9, PHS2, THP1, THP2 | -GLI2 and Bladder Cancer | 2 | |
SRPX | Xp11.4 | DRS, ETX1, SRPX1, HEL-S-83p | -SRPX and Bladder Cancer | 2 | |
RRM1 | 11p15.4 | R1, RR1, RIR1 | -RRM1 and Bladder Cancer | 2 | |
MAP2K4 | 17p12 | JNKK, MEK4, MKK4, SEK1, SKK1, JNKK1, SERK1, MAPKK4, PRKMK4, SAPKK1, SAPKK-1 | -MAP2K4 and Bladder Cancer | 2 | |
E2F2 | 1p36.12 | E2F-2 | -E2F2 and Bladder Cancer | 2 | |
BCL2L2 | 14q11.2 | BCLW, BCL-W, PPP1R51, BCL2-L-2 | -BCL2L2 and Bladder Cancer | 2 | |
TBX2 | 17q23.2 | -TBX2 and Bladder Cancer | 2 | ||
TACSTD2 | 1p32.1 | EGP1, GP50, M1S1, EGP-1, TROP2, GA7331, GA733-1 | -TACSTD2 and Bladder Cancer | 2 | |
RAD23B | 9q31.2 | P58, HR23B, HHR23B | -RAD23B and Bladder Cancer | 2 | |
FGF7 | 15q21.2 | KGF, HBGF-7 | -FGF7 and Bladder Cancer | 2 | |
CTAG1B | Xq28 | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | -CTAG1B and Bladder Cancer | 2 | |
EWSR1 | 22q12.2 | EWS, EWS-FLI1, bK984G1.4 | -EWSR1 and Bladder Cancer | 2 | |
WWOX | 16q23.1-q23.2 | FOR, WOX1, EIEE28, FRA16D, SCAR12, HHCMA56, PRO0128, SDR41C1, D16S432E | -WWOX and Bladder Cancer | 2 | |
DAB2IP | 9q33.2 | AIP1, AIP-1, AF9Q34, DIP1/2 | -DAB2IP and Bladder Cancer | 2 | |
MAPK1 | 22q11.22 | ERK, p38, p40, p41, ERK2, ERT1, ERK-2, MAPK2, PRKM1, PRKM2, P42MAPK, p41mapk, p42-MAPK | -MAPK1 and Bladder Cancer | 2 | |
NUMB | 14q24.2-q24.3 | S171, C14orf41, c14_5527 | -NUMB and Bladder Cancer | 2 | |
RHEB | 7q36.1 | RHEB2 | -RHEB and Bladder Cancer | 2 | |
PCDH10 | 4q28.3 | PCDH19, OL-PCDH | -PCDH10 and Bladder Cancer | 2 | |
CDKN2D | 19p13.2 | p19, INK4D, p19-INK4D | -CDKN2D and Bladder Cancer | 2 | |
MMP8 | 11q22.2 | HNC, CLG1, MMP-8, PMNL-CL | -MMP8 and Bladder Cancer | 2 | |
RALB | 2q14.2 | -RALB and Bladder Cancer | 2 | ||
HYAL1 | 3p21.31 | MPS9, NAT6, LUCA1, HYAL-1 | -HYAL1 and Bladder Cancer | 2 | |
IL4 | 5q31.1 | BSF1, IL-4, BCGF1, BSF-1, BCGF-1 | -IL4 and Bladder Cancer | 2 | |
FEZ1 | 11q24.2 | UNC-76 | -FEZ1 and Bladder Cancer | 2 | |
CYP2A13 | 19q13.2 | CPAD, CYP2A, CYPIIA13 | -CYP2A13 and Bladder Cancer | 2 | |
SPINK1 | 5q32 | TCP, PCTT, PSTI, TATI, Spink3 | -SPINK1 and Bladder Cancer | 2 | |
TAGLN | 11q23.3 | SM22, SMCC, TAGLN1, WS3-10 | -TAGLN and Bladder Cancer | 2 | |
CEACAM1 | 19q13.2 | BGP, BGP1, BGPI | -CEACAM1 and Bladder Cancer | 2 | |
NQO2 | 6p25.2 | QR2, DHQV, DIA6, NMOR2 | -NQO2 and Bladder Cancer | 2 | |
KISS1R | 19p13.3 | HH8, CPPB1, GPR54, AXOR12, KISS-1R, HOT7T175 | -KISS1R and Bladder Cancer | 2 | |
TBX3 | 12q24.21 | UMS, XHL, TBX3-ISO | -TBX3 and Bladder Cancer | 2 | |
MIR34A | 1p36.22 | mir-34, MIRN34A, mir-34a, miRNA34A | -MIR34A and Bladder Cancer | 2 | |
TLR3 | 4q35.1 | CD283, IIAE2 | -TLR3 and Bladder Cancer | 2 | |
BUB1 | 2q14 | BUB1A, BUB1L, hBUB1 | -BUB1 and Bladder Cancer | 2 | |
KLF5 | 13q22.1 | CKLF, IKLF, BTEB2 | -KLF5 and Bladder Cancer | 2 | |
IMP3 | 15q24.2 | BRMS2, MRPS4, C15orf12 | -IMP3 and Bladder Cancer | 2 | |
LAMB3 | 1q32.2 | AI1A, LAM5, LAMNB1, BM600-125KDA | -LAMB3 and Bladder Cancer | 2 | |
GLI3 | 7p14.1 | PHS, ACLS, GCPS, PAPA, PAPB, PAP-A, PAPA1, PPDIV, GLI3FL, GLI3-190 | -GLI3 and Bladder Cancer | 2 | |
JAG1 | 20p12.2 | AGS, AHD, AWS, HJ1, AGS1, DCHE, CD339, JAGL1 | -JAG1 and Bladder Cancer | 2 | |
GATA2 | 3q21.3 | DCML, IMD21, NFE1B, MONOMAC | -GATA2 and Bladder Cancer | 2 | |
HOXD10 | 2q31.1 | HOX4, HOX4D, HOX4E, Hox-4.4 | -HOXD10 and Bladder Cancer | 2 | |
MAD2L1 | 4q27 | MAD2, HSMAD2 | -MAD2L1 and Bladder Cancer | 2 | |
CXCL5 | 4q13.3 | SCYB5, ENA-78 | -CXCL5 and Bladder Cancer | 2 | |
SMARCA4 | 19p13.2 | BRG1, CSS4, SNF2, SWI2, MRD16, RTPS2, BAF190, SNF2L4, SNF2LB, hSNF2b, BAF190A | -SMARCA4 and Bladder Cancer | 2 | |
FLNA | Xq28 | FLN, FMD, MNS, OPD, ABPX, CSBS, CVD1, FGS2, FLN1, NHBP, OPD1, OPD2, XLVD, XMVD, FLN-A, ABP-280 | -FLNA and Bladder Cancer | 2 | |
MMP12 | 11q22.2 | ME, HME, MME, MMP-12 | -MMP12 and Bladder Cancer | 2 | |
IL4R | 16p12.1 | CD124, IL4RA, IL-4RA | -IL4R and Bladder Cancer | 2 | |
MBD2 | 18q21.2 | DMTase, NY-CO-41 | -MBD2 and Bladder Cancer | 2 | |
MCM2 | 3q21 | BM28, CCNL1, CDCL1, cdc19, D3S3194, MITOTIN | -MCM2 and Bladder Cancer | 2 | |
SDC4 | 20q13.12 | SYND4 | -SDC4 and Bladder Cancer | 2 | |
ERCC4 | 16p13.12 | XPF, RAD1, FANCQ, XFEPS, ERCC11 | -ERCC4 and Bladder Cancer | 2 | |
RHOBTB2 | 8p21.3 | DBC2 | -RHOBTB2 and Bladder Cancer | 2 | |
NOX4 | 11q14.3 | KOX, KOX-1, RENOX | -NOX4 and Bladder Cancer | 2 | |
IL17C | 16q24.2 | CX2, IL-17C | -IL17C and Bladder Cancer | 2 | |
AQP3 | 9p13.3 | GIL, AQP-3 | -AQP3 and Bladder Cancer | 2 | |
AIM1 | 6q21 | ST4, CRYBG1 | -AIM1 and Bladder Cancer | 2 | |
BCHE | 3q26.1-q26.2 | E1, CHE1, CHE2 | -BCHE and Bladder Cancer | 2 | |
EPHB4 | 7q22.1 | HTK, MYK1, HFASD, TYRO11 | -EPHB4 and Bladder Cancer | 2 | |
MCM4 | 8q11.21 | NKCD, CDC21, CDC54, NKGCD, hCdc21, P1-CDC21 | -MCM4 and Bladder Cancer | 2 | |
ENDOU | 12q13.1 | P11, PP11, PRSS26 | -ENDOU and Bladder Cancer | 1 | |
ESPL1 | 12q13.13 | ESP1, SEPA | GWS | -ESPL1 and Bladder Cancer | 1 |
SMPD1 | 11p15.4 | ASM, NPD, ASMASE | -SMPD1 and Bladder Cancer | 1 | |
LDLR | 19p13.2 | FH, FHC, LDLCQ2 | -LDLR and Bladder Cancer | 1 | |
LASP1 | 17q12 | MLN50, Lasp-1 | -LASP1 and Bladder Cancer | 1 | |
SPRR2B | 1q21.3 | -SPRR2B and Bladder Cancer | 1 | ||
TANK | 2q24.2 | ITRAF, TRAF2, I-TRAF | -TANK and Bladder Cancer | 1 | |
TRAF6 | 11p12 | RNF85, MGC:3310 | -TRAF6 and Bladder Cancer | 1 | |
AGTR2 | Xq23 | AT2, ATGR2, MRX88 | -AGTR2 and Bladder Cancer | 1 | |
BMPR2 | 2q33-q34 | BMR2, PPH1, BMPR3, BRK-3, POVD1, T-ALK, BMPR-II | -BMPR2 and Bladder Cancer | 1 | |
BUB3 | 10q26.13 | BUB3L, hBUB3 | -BUB3 and Bladder Cancer | 1 | |
MUC5B | 11p15.5 | MG1, MUC5, MUC9, MUC-5B | -MUC5B and Bladder Cancer | 1 | |
CXCL11 | 4q21.1 | IP9, H174, IP-9, b-R1, I-TAC, SCYB11, SCYB9B | -CXCL11 and Bladder Cancer | 1 | |
EEF1E1 | 6p24.3 | P18, AIMP3 | -EEF1E1 and Bladder Cancer | 1 | |
NEFL | 8p21.2 | NFL, NF-L, NF68, CMT1F, CMT2E, PPP1R110 | -NEFL and Bladder Cancer | 1 | |
SMARCA2 | 9p24.3 | BRM, SNF2, SWI2, hBRM, NCBRS, Sth1p, BAF190, SNF2L2, SNF2LA, hSNF2a | -SMARCA2 and Bladder Cancer | 1 | |
S100B | 21q22.3 | NEF, S100, S100-B, S100beta | -S100B and Bladder Cancer | 1 | |
MIRLET7D | 9q22.32 | LET7D, let-7d, MIRNLET7D, hsa-let-7d | -None and Bladder Cancer | 1 | |
CEBPB | 20q13.13 | TCF5, IL6DBP, NF-IL6, C/EBP-beta | -CEBPB and Bladder Cancer | 1 | |
ATP7B | 13q14.3 | WD, PWD, WC1, WND | -ATP7B and Bladder Cancer | 1 | |
GNL3 | 3p21.1 | NS, E2IG3, NNP47, C77032 | -GNL3 and Bladder Cancer | 1 | |
HDAC6 | Xp11.23 | HD6, JM21, CPBHM, PPP1R90 | -HDAC6 and Bladder Cancer | 1 | |
EML4 | 2p21 | C2orf2, ELP120, EMAP-4, EMAPL4, ROPP120 | -EML4 and Bladder Cancer | 1 | |
POLI | 18q21.2 | RAD30B, RAD3OB | -POLI and Bladder Cancer | 1 | |
WRN | 8p12 | RECQ3, RECQL2, RECQL3 | -WRN and Bladder Cancer | 1 | |
CREB3L1 | 11p11.2 | OASIS | -CREB3L1 and Bladder Cancer | 1 | |
ADH1C | 4q23 | ADH3 | -ADH1C and Bladder Cancer | 1 | |
RIN1 | 11q13.2 | -RIN1 and Bladder Cancer | 1 | ||
MAD1L1 | 7p22.3 | MAD1, PIG9, TP53I9, TXBP181 | -MAD1L1 and Bladder Cancer | 1 | |
MEG3 | 14q32.2 | GTL2, FP504, prebp1, PRO0518, PRO2160, LINC00023, NCRNA00023, onco-lncRNA-83 | -MEG3 and Bladder Cancer | 1 | |
IL23R | 1p31.3 | -IL23R and Bladder Cancer | 1 | ||
S100A1 | 1q21.3 | S100, S100A, S100-alpha | -S100A1 and Bladder Cancer | 1 | |
YWHAZ | 8q22.3 | HEL4, YWHAD, KCIP-1, HEL-S-3, HEL-S-93, 14-3-3-zeta | -YWHAZ and Bladder Cancer | 1 | |
ACVRL1 | 12q13.13 | HHT, ALK1, HHT2, ORW2, SKR3, ALK-1, TSR-I, ACVRLK1 | -ACVRL1 and Bladder Cancer | 1 | |
PLK2 | 5q11.2 | SNK, hSNK, hPlk2 | -PLK2 and Bladder Cancer | 1 | |
BCL2L12 | 19q13.33 | -BCL2L12 and Bladder Cancer | 1 | ||
HSD3B2 | 1p12 | HSDB, HSD3B, SDR11E2 | -HSD3B2 and Bladder Cancer | 1 | |
KIAA1524 | 3q13.13 | p90, CIP2A | -KIAA1524 and Bladder Cancer | 1 | |
MTSS1 | 8q24.13 | MIM, MIMA, MIMB | -MTSS1 and Bladder Cancer | 1 | |
TRIM24 | 7q33-q34 | PTC6, TF1A, TIF1, RNF82, TIF1A, hTIF1, TIF1ALPHA | -TRIM24 and Bladder Cancer | 1 | |
IL27 | 16p12.1-p11.2 | p28, IL30, IL-27, IL27A, IL-27A, IL27p28 | -IL27 and Bladder Cancer | 1 | |
FGFR4 | 5q35.2 | TKF, JTK2, CD334 | -FGFR4 and Bladder Cancer | 1 | |
NONO | Xq13.1 | P54, NMT55, NRB54, MRXS34, P54NRB, PPP1R114 | -NONO and Bladder Cancer | 1 | |
HDAC3 | 5q31.3 | HD3, RPD3, RPD3-2 | -HDAC3 and Bladder Cancer | 1 | |
ARF1 | 1q42.13 | PVNH8 | -ARF1 and Bladder Cancer | 1 | |
PSIP1 | 9p22.3 | p52, p75, PAIP, DFS70, LEDGF, PSIP2 | -PSIP1 and Bladder Cancer | 1 | |
CASP1 | 11q22.3 | ICE, P45, IL1BC | -CASP1 and Bladder Cancer | 1 | |
TNFRSF25 | 1p36.31 | DR3, TR3, DDR3, LARD, APO-3, TRAMP, WSL-1, GEF720, WSL-LR, PLEKHG5, TNFRSF12 | -TNFRSF25 and Bladder Cancer | 1 | |
TPTE | 21p11.2 | CT44, PTEN2 | -TPTE and Bladder Cancer | 1 | |
TNKS | 8p23.1 | TIN1, ARTD5, PARPL, TINF1, TNKS1, pART5, PARP5A, PARP-5a | -TNKS and Bladder Cancer | 1 | |
DLEC1 | 3p22.2 | F56, DLC1, DLC-1, CFAP81 | -DLEC1 and Bladder Cancer | 1 | |
MSI2 | 17q22 | MSI2H | -MSI2 and Bladder Cancer | 1 | |
OPCML | 11q25 | OPCM, OBCAM, IGLON1 | -OPCML and Bladder Cancer | 1 | |
HLA-E | 6p21.3 | MHC, QA1, EA1.2, EA2.1, HLA-6.2 | -HLA-E and Bladder Cancer | 1 | |
ELN | 7q11.23 | WS, WBS, SVAS | -ELN and Bladder Cancer | 1 | |
CASP2 | 7q34 | ICH1, NEDD2, CASP-2, NEDD-2, PPP1R57 | -CASP2 and Bladder Cancer | 1 | |
PTPRD | 9p24.1-p23 | HPTP, PTPD, HPTPD, HPTPDELTA, RPTPDELTA | -PTPRD and Bladder Cancer | 1 | |
ANO1 | 11q13.3 | DOG1, TAOS2, ORAOV2, TMEM16A | -ANO1 and Bladder Cancer | 1 | |
CSF3R | 1p34.3 | SCN7, CD114, GCSFR | -CSF3R and Bladder Cancer | 1 | |
IRAK1 | Xq28 | IRAK, pelle | -IRAK1 and Bladder Cancer | 1 | |
CHRNB4 | 15q25.1 | -CHRNB4 and Bladder Cancer | 1 | ||
S100A3 | 1q21.3 | S100E | -S100A3 and Bladder Cancer | 1 | |
DRD2 | 11q23.2 | D2R, D2DR | -DRD2 and Bladder Cancer | 1 | |
NUMA1 | 11q13.4 | NUMA, NMP-22 | -NUMA1 and Bladder Cancer | 1 | |
IDO1 | 8p11.21 | IDO, INDO, IDO-1 | -IDO1 and Bladder Cancer | 1 | |
IRF7 | 11p15.5 | IMD39, IRF7A, IRF7B, IRF7C, IRF7H, IRF-7H | -IRF7 and Bladder Cancer | 1 | |
CBX7 | 22q13.1 | -CBX7 and Bladder Cancer | 1 | ||
SHMT1 | 17p11.2 | SHMT, CSHMT | -SHMT1 and Bladder Cancer | 1 | |
NRG1 | 8p12 | GGF, HGL, HRG, NDF, ARIA, GGF2, HRG1, HRGA, SMDF, MST131, MSTP131, NRG1-IT2 | -NRG1 and Bladder Cancer | 1 | |
RASAL1 | 12q24.13 | RASAL | -RASAL1 and Bladder Cancer | 1 | |
KAT5 | 11q13.1 | TIP, ESA1, PLIP, TIP60, cPLA2, HTATIP, ZC2HC5, HTATIP1 | -KAT5 and Bladder Cancer | 1 | |
MSI1 | 12q24 | -MSI1 and Bladder Cancer | 1 | ||
LHCGR | 2p21 | HHG, LHR, LCGR, LGR2, ULG5, LHRHR, LSH-R, LH/CGR, LH/CG-R | -LHCGR and Bladder Cancer | 1 | |
AMFR | 16q13 | GP78, RNF45 | -AMFR and Bladder Cancer | 1 | |
IRF9 | 14q12 | p48, IRF-9, ISGF3, ISGF3G | -IRF9 and Bladder Cancer | 1 | |
DGCR8 | 22q11.21 | Gy1, pasha, DGCRK6, C22orf12 | -DGCR8 and Bladder Cancer | 1 | |
PNN | 14q21.1 | DRS, DRSP, SDK3, memA | -PNN and Bladder Cancer | 1 | |
CASP5 | 11q22.3 | ICH-3, ICEREL-III, ICE(rel)III | -CASP5 and Bladder Cancer | 1 | |
IL17A | 6p12.2 | IL17, CTLA8, IL-17, CTLA-8, IL-17A | -IL17A and Bladder Cancer | 1 | |
MIR106A | Xq26.2 | mir-106, MIRN106A, mir-106a | -MIR106A and Bladder Cancer | 1 | |
KLK6 | 19q13.41 | hK6, Bssp, Klk7, SP59, PRSS9, PRSS18 | -KLK6 and Bladder Cancer | 1 | |
IL12B | 5q33.3 | CLMF, NKSF, CLMF2, IMD28, IMD29, NKSF2, IL-12B | -IL12B and Bladder Cancer | 1 | |
PPP2CB | 8p12 | PP2CB, PP2Abeta | -PPP2CB and Bladder Cancer | 1 | |
ITGA6 | 2q31.1 | CD49f, VLA-6, ITGA6B | -ITGA6 and Bladder Cancer | 1 | |
PGK1 | Xq21.1 | PGKA, MIG10, HEL-S-68p | -PGK1 and Bladder Cancer | 1 | |
RCVRN | 17p13.1 | RCV1 | -RCVRN and Bladder Cancer | 1 | |
LTB | 6p21.33 | p33, TNFC, TNFSF3, TNLG1C | -LTB and Bladder Cancer | 1 | |
FABP5 | 8q21.13 | EFABP, KFABP, E-FABP, PAFABP, PA-FABP | -FABP5 and Bladder Cancer | 1 | |
EIF4EBP1 | 8p11.23 | BP-1, 4EBP1, 4E-BP1, PHAS-I | -EIF4EBP1 and Bladder Cancer | 1 | |
ITGA4 | 2q31.3 | IA4, CD49D | -ITGA4 and Bladder Cancer | 1 | |
S100A7 | 1q21.3 | PSOR1, S100A7c | -S100A7 and Bladder Cancer | 1 | |
SLC7A5 | 16q24.2 | E16, CD98, LAT1, 4F2LC, MPE16, D16S469E | -SLC7A5 and Bladder Cancer | 1 | |
UGT2B17 | 4q13.2 | BMND12, UDPGT2B17 | -UGT2B17 and Bladder Cancer | 1 | |
MYOD1 | 11p15.1 | PUM, MYF3, MYOD, bHLHc1 | -MYOD1 and Bladder Cancer | 1 | |
LRIG3 | 12q14.1 | LIG3 | -LRIG3 and Bladder Cancer | 1 | |
TYK2 | 19p13.2 | JTK1, IMD35 | -TYK2 and Bladder Cancer | 1 | |
HTRA1 | 10q26.13 | L56, HtrA, ARMD7, ORF480, PRSS11, CARASIL, CADASIL2 | -HTRA1 and Bladder Cancer | 1 | |
PBRM1 | 3p21.1 | PB1, BAF180 | -PBRM1 and Bladder Cancer | 1 | |
SNRPE | 1q32.1 | SME, Sm-E, HYPT11, snRNP-E | -SNRPE and Bladder Cancer | 1 | |
KLK5 | 19q13.41 | SCTE, KLKL2, KLK-L2 | -KLK5 and Bladder Cancer | 1 | |
CAV2 | 7q31.2 | CAV | -CAV2 and Bladder Cancer | 1 | |
MYCL | 1p34.2 | LMYC, L-Myc, MYCL1, bHLHe38 | -MYCL and Bladder Cancer | 1 | |
PDCD6 | 5p15.33 | ALG2, ALG-2, PEF1B | -PDCD6 and Bladder Cancer | 1 | |
NRP2 | 2q33.3 | NP2, NPN2, PRO2714, VEGF165R2 | -NRP2 and Bladder Cancer | 1 | |
FOXO4 | Xq13.1 | AFX, AFX1, MLLT7 | -FOXO4 and Bladder Cancer | 1 | |
GRASP | 12q13.13 | TAMALIN | -GRASP and Bladder Cancer | 1 | |
IL12A | 3q25.33 | P35, CLMF, NFSK, NKSF1, IL-12A | -IL12A and Bladder Cancer | 1 | |
AIFM1 | Xq26.1 | AIF, AUNX1, CMT2D, CMTX4, COWCK, DFNX5, NADMR, NAMSD, PDCD8, COXPD6 | -AIFM1 and Bladder Cancer | 1 | |
PPP1R13L | 19q13.32 | RAI, RAI4, IASPP, NKIP1 | -PPP1R13L and Bladder Cancer | 1 | |
HOXA13 | 7p15.2 | HOX1, HOX1J | -HOXA13 and Bladder Cancer | 1 | |
SOD1 | 21q22.11 | ALS, SOD, ALS1, IPOA, hSod1, HEL-S-44, homodimer | -SOD1 and Bladder Cancer | 1 | |
SLCO1B1 | 12p12.1 | LST1, HBLRR, LST-1, OATP2, OATPC, OATP-C, OATP1B1, SLC21A6 | -SLCO1B1 and Bladder Cancer | 1 | |
FGF19 | 11q13.3 | -FGF19 and Bladder Cancer | 1 | ||
ALOX5 | 10q11.21 | 5-LO, 5LPG, LOG5, 5-LOX | -ALOX5 and Bladder Cancer | 1 | |
ATIC | 2q35 | PURH, AICAR, AICARFT, IMPCHASE, HEL-S-70p | -ATIC and Bladder Cancer | 1 | |
SLCO1B3 | 12p12.2 | LST3, HBLRR, LST-2, OATP8, OATP-8, OATP1B3, SLC21A8, LST-3TM13 | -SLCO1B3 and Bladder Cancer | 1 | |
NSD3 | 8p11.23 | KMT3F, KMT3G, WHISTLE, WHSC1L1, pp14328 | -WHSC1L1 and Bladder Cancer | 1 | |
TES | 7q31.2 | TESS, TESS-2 | -TES and Bladder Cancer | 1 | |
ITGB4 | 17q25.1 | CD104, GP150 | -ITGB4 and Bladder Cancer | ||
PDLIM4 | 5q31.1 | RIL | -PDLIM4 and Bladder Cancer | ||
MAPK3 | 16p11.2 | ERK1, ERT2, ERK-1, PRKM3, P44ERK1, P44MAPK, HS44KDAP, HUMKER1A, p44-ERK1, p44-MAPK | -MAPK3 and Bladder Cancer | ||
TUBE1 | 6q21 | TUBE, dJ142L7.2 | -TUBE1 and Bladder Cancer |
Note: list is not exhaustive. Number of papers are based on searches of PubMed (click on topic title for arbitrary criteria used).
Selected list of common recurrent structural abnormalities
Abnormality | Type | Gene(s) | |
del(9q) in Bladder Cancer | Deletion | ||
Chromosome Y Loss in Bladder Cancer | Loss |
This is a highly selective list aiming to capture structural abnormalies which are frequesnt and/or significant in relation to diagnosis, prognosis, and/or characterising specific cancers. For a much more extensive list see the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer.
Loss of heterozygosity (LOH) on chromosome arm 9 is the most frequent genetic alteration in transitional cell carcinomas. Candidate tumor suppressor genes/loci have been proposed, including: CDKN2 and DBCCR1.
Disclaimer: This site is for educational purposes only; it can not be used in diagnosis or treatment.
Cite this page: Cotterill SJ. Bladder Cancer - Molecular Biology, Cancer Genetics Web: http://www.cancer-genetics.org/X2103.htm Accessed:
This page in Cancer Genetics Web by Simon Cotterill is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Note: content of abstracts copyright of respective publishers - seek permission where appropriate.
[Home] Page last revised: 29 August, 2019 Cancer Genetics Web, Established 1999